戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (right1)

通し番号をクリックするとPubMedの該当ページを表示します
1                Metastases have been observed, and long-term follow-up is needed.
2 allergic rhinitis and intrinsic rhinitis, although a longer follow-up is needed.
3 tinopathy occurs in 2.9% of eyes over 24 months, but longer follow-up is needed.
4 d is preferable to the current standard of care, but longer follow-up is needed.
5 at least equivalent to contemporary open series, but longer follow-up is needed.
6 f graft loss from recurrent GN in the short term but longer follow-up is needed.
7 on of renal tumors completely in one session, but long-term follow-up is needed.
8              Initial results are promising; however, longer follow-up is needed and more patients must be studied.
9 he ROP recurrence rate is higher, and vigilant and extended follow-up is needed because retinal vascularization is usuall
10 vidence of a mortality reduction in years 7-14, but further follow-up is needed before firm conclusions can be reached on
11                                             Although longer follow-up is needed, our results might help identify, among c
12                                        Although longer-term follow-up is needed, ranibizumab may be a reasonable treatmen
13                                             Although longer follow-up is needed, these in utero data are reassuring and s
14                                            Although further follow-up is needed, these results may be useful in counselin
15                                                      Longer follow-up is needed to ascertain resolution or worsening of c
16                                                    Extended follow-up is needed to ascertain the magnitude and stability
17                                                     Further follow-up is needed to assess long-term effects on health out
18                                                 Longer term follow-up is needed to assess the durability of quality-of-li
19                                                     Further follow-up is needed to assess the effect on breast cancer mor
20                                                     Further follow-up is needed to assess the potential effect of bevaciz
21                                                 Longer-term follow-up is needed to better assess the mortality risk.
22                                                 Longer term follow-up is needed to better understand the clinical impact
23                                                      Longer follow-up is needed to better understand the effect of COVID-
24                                                      Longer follow-up is needed to characterize second tumor risks in the
25                                                   Long-term follow-up is needed to clarify this issue.
26                     Further research, including longer-term follow-up is needed to confirm these findings.
27      Although there seems to be less early toxicity, longer follow-up is needed to determine late effects, especially the
28                                                   Continued follow-up is needed to determine the clinical significance of
29                                                      Longer follow-up is needed to determine the impact of (18)F-fluciclo
30                                                      Longer follow-up is needed to determine the relationship of these fi
31                                      CONCLUSION.: Long-term follow-up is needed to determine the role of Luminex-based st
32                                                   Long-term follow-up is needed to determine the visual significance of t
33                                                      Longer follow-up is needed to determine whether monitoring the rate
34 hort-term incidence of progressive MR is low; however, more follow-up is needed to determine whether patients with MVP an
35                                                   Long-term follow-up is needed to determine whether some patients have a
36                                                  Additional follow-up is needed to determine whether the statistically si
37 ant referral for patients on dialysis in Georgia; long-term follow-up is needed to determine whether these effects led to
38                                                     Further follow-up is needed to determine whether these improvements w
39                                                      Longer follow-up is needed to ensure that the improvement in breast
40                                                   Long-term follow-up is needed to establish durable oncologic efficacy a
41                                     Completion of long-term follow-up is needed to establish the efficacy of carotid arte
42                                                 Longer-term follow-up is needed to establish their effect on the healing
43                                                  Additional follow-up is needed to establish whether these associations p
44                                                      Longer follow-up is needed to evaluate the impact of ME on other asp
45 tions that can occur with femtosecond lasers, and long-term follow-up is needed to evaluate the technology fully.
46                                                  Additional follow-up is needed to fully assess the duration of response
47                                                      Longer follow-up is needed to further assess safety outcomes and per
48                                                      Longer follow-up is needed to identify an effect on the primary endp
49 k among predominately premenopausal women; however, further follow-up is needed to increase power for subgroup analyses.
50                                                      Longer follow-up is needed to see whether these decreases are associ